Cyclobenzaprine HCI | Cyclobenzaprine hydrochloride | MK130 hydrochloride;Cyclobenzaprine (hydrochloride) (CRM);MK-130;Cyclobenzaprine HCl | 环苯扎林盐酸盐 | Other Compounds | 5-HT Receptor

首页 / / / / Cyclobenzaprine HCI

盐酸环苯扎林 /Cyclobenzaprine HCI {[allProObj[0].p_purity_real_show]}

货号：A210756 同义名： 环苯扎林盐酸盐 / MK130 hydrochloride;Cyclobenzaprine (hydrochloride) (CRM)

Cyclobenzaprine HCI是一种5-HT2受体拮抗剂，作为骨骼肌松弛剂和中枢神经系统（CNS）抑制剂，半衰期为32小时。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Cyclobenzaprine HCI 化学结构
CAS号：6202-23-9

Cyclobenzaprine HCI 3D分子结构
CAS号：6202-23-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Cyclobenzaprine HCI 纯度/质量文件产品仅供科研

货号：A210756 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]; • Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]; • ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]; • Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]; 更多 >

5-羟色胺受体亚型比较

产品名称	5-HT ↓ ↑	5-HT1 ↓ ↑	5-HT2 ↓ ↑	5-HT3 ↓ ↑	5-HT5 ↓ ↑	5-HT6 ↓ ↑	5-HT7 ↓ ↑	其他靶点	纯度
Desvenlafaxine	++ 5-HT, Ki: 40.2 nM								98%
Lamotrigine	+ 5-HT (rat brain synaptosomes), IC50: 474 μM 5-HT (human platelets), IC50: 240 μM								98%
Venlafaxine	✔								99%
Fluvoxamine maleate	✔								99%
Iloperidone	✔								99%
Ziprasidone HCl	✔								98+%
Atomoxetine HCI	+ 5-HT, Ki: 77 nM								98%
Dapoxetine HCl	✔								97%
Trazodone	✔								98+%
Clomipramine HCl	✔								98%
Mirtazapine	✔								99+%
Escitalopram oxalate	+++ 5-HT, Ki: 0.89 nM								97%
Duloxetine	✔								98+%
Sertraline HCl	++ 5-HT, Ki: 13 nM								98%
Citalopram HBr	+++ serotonin reuptake, IC50: 1.8 nM								98%
Latrepirdine 2HCl	✔							GluR	99%
Fluoxetine HCl	✔								99.5%
Paroxetine hydrochloride	✔							AChR	99%
BMY 7378		++ 5-HT1A, pIC50: 6.4 5-HT1D, pIC50: 5.9	+ 5-HT2, pIC50: 5.5						97%
Flibanserin		+++ 5-HT1A, Ki: 1 nM	+ 5-HT2A, Ki: 49 nM						98%
LY310762		+ 5-HT1D, Ki: 249 nM							99%+
Cyclobenzaprine HCI			✔						99%
Blonanserin			+++ 5-HT2, Ki: 3.98 nM						99%
Cyproheptadine HCl			++++ 5-HT2, IC50: 0.6 nM						99+%
Olanzapine			✔						99+%
Pimavanserin hemitartrate			+++ 5-HT2A, pIC50: 8.7						99%
Ketanserin			+++ 5-HT2C (Human), Ki: 2.5 nM 5-HT2C (Rat), Ki: 50 nM						99%+
Loxapine succinate			++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM						99%
Agomelatine			✔						98%
Clozapine			✔						98%
Amitriptyline			+ 5-HT2, Ki: 235 nM					SERT	99%
PRX-08066 maleate			+++ 5-HT2B, IC50: 3.4 nM						98+%
RS-127445			++++ 5-HT2B, pKi: 9.5 5-HT2B, pIC50: 10.4						99%+
Sarpogrelate HCl			++++ 5-HT2C, Kd: 1.1 nM 5-HT2A, Kd: 2.1 nM						98%
Tropisetron				✔					99%
Palonosetron				✔					98%
Ramosetron HCl				++++ 5-HT3 receptor, Ki: 0.091 nM					98%
Ondansetron				✔					99%
Granisetron				✔					98%
Alosetron HCl				✔					98%
Ondansetron hydrochloride dihydrate				✔					98%
VUF10166				++++ 5-HT3A, Ki: 0.04 nM 5-HT3AB, Ki: 22 nM					99%+
Azasetron hydrochloride				++++ 5-HT3, IC50: 0.33 nM					99%
Asenapine maleate		+++ 5-HT1A, pKi: 8.6 5-HT1B, pKi: 8.4	++++ 5-HT2A, pKi: 9.75 5-HT2C, pKi: 10.46		+++ 5-HT5A, pKi: 8.84	++++ 5-HT6, pKi: 9.6	++++ 5-HT7, pKi: 9.94		97%
Risperidone		++ 5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM	++++ 5-HT2C, Ki: 12 nM 5-HT2A, Ki: 61.9 nM		+ 5-HT5A, Ki: 206 nM		++ 5-HT7, Ki: 6.6 nM		98%
SB 271046 HCl						+++ 5-HT6, pKi: 8.92			99%+
Intepirdine						++++ 5-HT6, pKi: 9.63			99%+
SB-269970 HCl							++ 5-HT7, pKi: 8.3		98+%
BRL 15572		++ 5-HT1B, pKi: 6.1 5-HT1D, pKi: 6	++ 5-HT2B, pKi: 6.2 5-HT2A, pKi: 6.6			+ 5-HT6, pKi: 5.9	+ 5-HT7, pKi: 6.3		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cyclobenzaprine HCI 生物活性

靶点

5-HT2

描述

Cyclobenzaprine HCl, 5-HT2 receptor antagonist, is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine (HCl) was thought to be an alpha 2-adrenoceptor agonist that reduced muscle tone by decreasing the activity of descending noradrenergic neurons. Cyclobenzaprine reduced the monosynaptic reflex amplitude dose dependently and this effect was not inhibited by the alpha 2-adrenoceptor antagonists idazoxan and yohimbine. However, cyclobenzaprine inhibited monosynaptic reflex facilitation induced by (+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane, a 5-HT2 receptor agonist, in spinalized rats markedly, and 5-HT depletion by DL-p-chlorophenylalanine inhibited the depressive effect of cyclobenzaprine on the monosynaptic reflex^[2]. The inhibitory effects of cyclobenzaprine on mono- and polysynaptic reflex potentials are due to the inhibition of descending serotonergic systems through 5-HT(2) receptors in the spinal cord^[1]. Owing to its anticholinergic activity and long half-life, cyclobenzaprine is not recommended for use in the elderly^[3].

Cyclobenzaprine HCI 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02891759	Breast Cancer	Phase 2	Recruiting	April 30, 2020	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Terence M Myckatyn, M.D. 314-996-8800 myckatyn@wustl.edu Principal Investigator: Terence M Myckatyn, M.D. Sub-Investigator: Marissa Tenenbaum, M.D. Sub-Investigator: Julie Margenthaler, M.D. Sub-Investigator: Amy Cyr, M.D. Sub-Investigator: Raj Parikh, M.D. Sub-Investigator: Elizabeth B Odom, M.D. 收起 <<
NCT00386243	Low Back Pain ... 展开 >> Pain Pain, Intractable 收起 <<	Not Applicable	Completed	-	United States, Indiana ... 展开 >> Richard Roudebush VA Medical Center, Indianapolis Indianapolis, Indiana, United States, 46202-2884 收起 <<
NCT02651324	Idiopathic Scoliosis ... 展开 >> Post-operative Pain 收起 <<	Phase 4	Active, not recruiting	December 2017	United States, New York ... 展开 >> Albany Medical Center Albany, New York, United States, 12208 收起 <<

Cyclobenzaprine HCI 参考文献

[1]Honda M, Nishida T, Ono H. Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003;458(1-2):91‐99

[2]Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996;311(1):29‐35

[3]Long-term Use of Cyclobenzaprine for Pain: A Review of the Clinical Effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015

Cyclobenzaprine HCI 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.21mL

0.64mL

0.32mL

16.03mL

3.21mL

1.60mL

32.07mL

6.41mL

3.21mL

Cyclobenzaprine HCI 技术信息

CAS号	6202-23-9
分子式	C₂₀H₂₂ClN
分子量	311.848

别名	环苯扎林盐酸盐 ;MK130 hydrochloride;Cyclobenzaprine (hydrochloride) (CRM);MK-130;Cyclobenzaprine HCl
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere,Room Temperature

溶解度

DMSO: 50 mg/mL(160.33 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 100 mg/mL(320.67 mM)

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02891759	Breast Cancer	Phase 2	Recruiting	April 30, 2020	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Terence M Myckatyn, M.D. 314-996-8800 myckatyn@wustl.edu Principal Investigator: Terence M Myckatyn, M.D. Sub-Investigator: Marissa Tenenbaum, M.D. Sub-Investigator: Julie Margenthaler, M.D. Sub-Investigator: Amy Cyr, M.D. Sub-Investigator: Raj Parikh, M.D. Sub-Investigator: Elizabeth B Odom, M.D. 收起 <<
NCT00386243	Low Back Pain ... 展开 >> Pain Pain, Intractable 收起 <<	Not Applicable	Completed	-	United States, Indiana ... 展开 >> Richard Roudebush VA Medical Center, Indianapolis Indianapolis, Indiana, United States, 46202-2884 收起 <<
NCT02651324	Idiopathic Scoliosis ... 展开 >> Post-operative Pain 收起 <<	Phase 4	Active, not recruiting	December 2017	United States, New York ... 展开 >> Albany Medical Center Albany, New York, United States, 12208 收起 <<
NCT02707094	Chronic Low Back Pain	Not Applicable	Completed	-	United States, Texas ... 展开 >> Brooke Army Medical Center Fort Sam Houston, Texas, United States, 78234 收起 <<
NCT02202369	Single Level Lumbar Decompress... 展开 >>ion and Fusion Spine Surgery 收起 <<	Phase 4	Recruiting	March 2022	United States, North Carolina ... 展开 >> OrthoCarolina Recruiting Charlotte, North Carolina, United States, 28207 Contact: Susan M Odum, PhD 704-323-2265 Susan.Odum@OrthoCarolina.com Contact: Christi Cadd, MBA 704.323.2260 christi.cadd@orthocarolina.com Sub-Investigator: Bruce Darden, MD Sub-Investigator: Eric Laxer, MD Principal Investigator: Alden Milam, MD Sub-Investigator: Alfred Rhyne, MD Sub-Investigator: Bradley Segebarth, MD Sub-Investigator: Leo Spector, MD 收起 <<
NCT00386243	-		Completed	-	-
NCT03508700	PTSD	Phase 3	Enrolling by invitation	September 2019	United States, Arkansas ... 展开 >> Little Rock Little Rock, Arkansas, United States, 72211 United States, California Beverly Hills Beverly Hills, California, United States, 90210 Oceanside Oceanside, California, United States, 92056 Orange Orange, California, United States, 92868 Temecula Temecula, California, United States, 92591 United States, Colorado Colorado Springs Colorado Springs, Colorado, United States, 80910 United States, Connecticut Norwich Norwich, Connecticut, United States, 06360 United States, Florida Tampa Tampa, Florida, United States, 33609 United States, Georgia Atlanta Atlanta, Georgia, United States, 30341 United States, Massachusetts New Bedford New Bedford, Massachusetts, United States, 02740 United States, Nevada Las Vegas Las Vegas, Nevada, United States, 89102 United States, New York Cedarhurst Cedarhurst, New York, United States, 11516 New York New York, New York, United States, 10128 United States, Ohio Canton Canton, Ohio, United States, 44718 Cincinnati Cincinnati, Ohio, United States, 45219 United States, Oklahoma Oklahoma City Oklahoma City, Oklahoma, United States, 73103 收起 <<
NCT02277704	PTSD	Phase 2	Completed	-	-
NCT03207828	Fibromyalgia ... 展开 >>Depression 收起 <<	Not Applicable	Recruiting	May 31, 2019	Chile ... 展开 >> Red Salud UC Christus Recruiting Santiago, Chile, Macul Contact: Josefina Durán, MA jgduran@uc.cl Contact: Matías González, PhD magonza@med.puc.cl 收起 <<
NCT01028014	Urethral Sphincter Activity	Not Applicable	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham, The Kirklin Clinic Birmingham, Alabama, United States, 35233 收起 <<
NCT02436096	Fibromyalgia ... 展开 >>Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases Rheumatic Diseases 收起 <<	Phase 3	Completed	-	-
NCT02403687	-		Completed	-	-
NCT02015234	Primary Fibromyalgia	Phase 3	Completed	-	United States, Colorado ... 展开 >> Denver Denver, Colorado, United States, 80239 United States, Florida 16176 Cortez Boulevard Brooksville, Florida, United States, 34601 100 West Gore Street Orlando, Florida, United States, 32806 United States, Maryland 71 Thomas Johnson Drive Frederick, Maryland, United States, 21702 United States, Massachusetts 370 Faunce Corner Road North Dartmouth, Massachusetts, United States, 02747 Worcester Worcester, Massachusetts, United States, 01605 United States, Mississippi Jackson Jackson, Mississippi, United States, 39202 United States, Ohio Cincinnati Cincinnati, Ohio, United States, 45219 1275 Olentangy River Road Columbus, Ohio, United States, 43212 18660 Bagley Road Middleburg Heights, Ohio, United States, 44130 United States, Pennsylvania 1001 South Market Street Mechanicsburg, Pennsylvania, United States, 17055 United States, South Carolina 322 Memorial Drive Greer, South Carolina, United States, 29650 United States, Washington 601 Broadway Seattle, Washington, United States, 98122 收起 <<
NCT01028014	-		Completed	-	-
NCT03110575	PTSD	Phase 3	Terminated(Stopped early due t... 展开 >>o inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301) 收起 <<	-	-
NCT02015234	-		Completed	-	-
NCT02974166	Temporomandibular Disorder	Not Applicable	Completed	-	Brazil ... 展开 >> Brazilian Institute of Osteopathy Porto Alegre, Rio Grande do Sul, Brazil 收起 <<
NCT01587274	Acute Low Back Pain	Phase 4	Completed	-	United States, New York ... 展开 >> Montefiore Medical Center Bronx, New York, United States, 10467 收起 <<
NCT01587274	-		Completed	-	-
NCT02589275	Primary Fibromyalgia	Phase 3	Terminated(For business reason... 展开 >> unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia development with TNX102 SL.) 收起 <<	-	-
NCT01903265	-		Completed	-	-
NCT02421679	PTSD	Phase 2	Completed	-	United States, Alabama ... 展开 >> Tuscaloosa VA Medical Center Tuscaloosa, Alabama, United States, 35404 United States, Arizona Noesis Pharma Phoenix, Arizona, United States, 85032 United States, California Sun Valley Reserach Center Imperial, California, United States, 92251 Synergy Clinical Research National City, California, United States, 91950 Excell Research, Inc Oceanside, California, United States, 92506 Neuropsychiatric Research Center of Orange County Orange, California, United States, 92868 CITRIALS Riverside, California, United States, 92506 CESAMH San Diego, California, United States, 92103 Cns, Inc. Torrance, California, United States, 90502 United States, Florida Sarkis Clinical Trials Lake City, Florida, United States, 32025 Compass Research North, LLC Leesburg, Florida, United States, 34748 Clinical Neuroscience Solutions, Inc. Orlando, Florida, United States, 32801 United States, Georgia Atlanta Center For Medical Research Atlanta, Georgia, United States, 30308 United States, Illinois Great Lakes Clinical Trials Chicago, Illinois, United States, 60640 United States, Massachusetts Novex Clinical Research New Bedford, Massachusetts, United States, 02740 United States, Nebraska Premier Psychiatric Research Instititute, Inc. Lincoln, Nebraska, United States, 68526 United States, Nevada Altea Research Las Vegas, Nevada, United States, 89102 United States, New York Neurobehavioral Research, Inc. Cedarhurst, New York, United States, 11516 United States, Ohio University of Cincinnati College of Medicine Cincinnati, Ohio, United States, 45219 University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 United States, Texas Clinical Trials of Texas San Antonio, Texas, United States, 78229 United States, Washington Northwest Clinical Research Center Bellevue, Washington, United States, 98007 收起 <<
NCT02497066	Pain	Phase 3	Enrolling by invitation	January 2019	-
NCT00635037	Myofascial Pain Syndromes	Not Applicable	Completed	-	Brazil ... 展开 >> Pain Setor of Federal University of Sao Paulo Sao Paulo, SP, Brazil 收起 <<
NCT02829814	Fibromyalgia ... 展开 >>Myofascial Pain Syndromes Muscular Diseases Nervous System Diseases Neuromuscular Diseases Rheumatic Diseases Musculoskeletal Diseases 收起 <<	Phase 3	Terminated(For business reason... 展开 >> unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia development with TNX102 SL.) 收起 <<	-	-
NCT01903265	Primary Fibromyalgia	Phase 2 Phase 3	Completed	-	United States, California ... 展开 >> 107 Scripps Drive Sacramento, California, United States, 95825 United States, Colorado Radiant Research, Inc. Denver, Colorado, United States, 80239 United States, Florida 16176 Cortez Boulevard Brooksville, Florida, United States, 34601 100 West Gore Street Orlando, Florida, United States, 32806 United States, Illinois 3401 North Central Avenue Chicago, Illinois, United States, 60634 United States, Maryland 71 Thomas Johnson Drive Frederick, Maryland, United States, 21702 United States, Massachusetts 370 Faunce Corner Road North Dartmouth, Massachusetts, United States, 02747 Clinical Pharmacology Study Group Worcester, Massachusetts, United States, 01605 United States, Mississippi CRC of Jackson, LLC Jackson, Mississippi, United States, 39202 United States, Ohio University of Cincinnati College of Medicine Cincinnati, Ohio, United States, 45219 1275 Olentangy River Road Columbus, Ohio, United States, 43212 18660 Bagley Road Middleburg Heights, Ohio, United States, 44130 United States, Pennsylvania 1001 South Market Street Mechanicsburg, Pennsylvania, United States, 17055 United States, South Carolina 322 Memorial Drive Greer, South Carolina, United States, 29650 United States, Utah 1002 E. South Temple Salt Lake City, Utah, United States, 84102 United States, Washington 1951 152nd Place NE Bellevue, Washington, United States, 98007 601 Broadway Seattle, Washington, United States, 98122 收起 <<
NCT03127592	Pain, Acute	Phase 3	Not yet recruiting	December 18, 2018	-
NCT01421433	Low Back Pain	Phase 3	Unknown	January 2013	Brazil ... 展开 >> Hospital São Luiz Not yet recruiting São Paulo, Brazil, 05673-050 Contact: Rogerio T. Silva 551181716767 rogerio@neo.org.br 收起 <<
NCT02862977	Musculoskeletal Pain	Phase 3	Not yet recruiting	June 29, 2018	-
NCT03025113	Musculoskeletal Pain	Phase 3	Not yet recruiting	January 30, 2019	-
NCT03062540	PTSD	Phase 3	Terminated(Stopped early due t... 展开 >>o inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.) 收起 <<	-	-
NCT03168022	Healthy Adults	Phase 1	Completed	-	Canada ... 展开 >> InVentiv Health Clinique Inc. Quebec, Canada, GIP )A2 收起 <<
NCT01689259	Healthy Adults	Phase 1	Completed	-	Canada, Quebec ... 展开 >> PharmaNet, Inc. Quebec City, Quebec, Canada, G1P 0A2 收起 <<
NCT01889173	Healthy Adults	Phase 1	Completed	-	Canada, Quebec ... 展开 >> PharmaNet, Inc. Quebec City, Quebec, Canada, G1P 0A2 收起 <<
NCT01587508	Acute Lumbago	Phase 3	Withdrawn(The comparator produ... 展开 >>ct was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned.) 收起 <<	-	Brazil ... 展开 >> Clínica de Ortopedia e Fraturas de Goiânia Goiania, GO, Brazil CIP Pesquisas Médicas Ltda Goiânia -, GO, Brazil Santa Casa de Misericórdia de Belo Horizonte Belo Horizonte, MG, Brazil Santa Casa de Juíz de Fora Juiz de Fora, MG, Brazil Hospital de Clínicas de Porto Alegre Porto Alegre, RS, Brazil Faculdade de Medicina ABC Santo Andre,, SP, Brazil Clinica de Ortopedia e Fisiatria Perdizes São Paulo, SP, Brazil Hospital Santa Marcelina São Paulo, SP, Brazil IMA Brasil São Paulo, SP, Brazil Santa Casa de Votuporanga Votuporanga, SP, Brazil Hospítal de Base São José Rio Preto, São Paulo, Brazil 收起 <<
NCT00790270	-		Completed	-	-
NCT00913419	Depression	Phase 1	Completed	-	-
NCT01490788	Healthy	Phase 1	Completed	-	Canada, Quebec ... 展开 >> PharmaNet, Inc. Québec City, Quebec, Canada, G1P 0A2 收起 <<
NCT01634412	Healthy Adults	Phase 1	Completed	-	Canada, Quebec ... 展开 >> PharmaNet, Inc. Quebec City, Quebec, Canada, G1P 0A2 收起 <<
NCT01081990	Postoperative Pain	Not Applicable	Unknown	December 2013	United States, Illinois ... 展开 >> Evanston NorthShore University HealthSystem Recruiting Evanston, Illinois, United States, 60201 Contact: Manhan K Vu, DO 847-570-2750 Principal Investigator: Manhan K Vu, DO 收起 <<
NCT01490788	-		Completed	-	-
NCT00246389	Pain Spasm	Phase 4	Completed	-	-
NCT01041495	Fibromyalgia ... 展开 >>Pain Sleep Fatigue 收起 <<	Phase 4	Unknown	March 2013	United States, New York ... 展开 >> SUNY Upstate Medical University Recruiting Syracuse, New York, United States, 13210 Contact: thomas l schwartz, md 315-464-3166 schwartt@upstate.edu Principal Investigator: Thomas L Schwartz, MD 收起 <<
NCT02814565	Neck Pain Bac... 展开 >>k Pain Spasm 收起 <<	Phase 3	Completed	-	Russian Federation ... 展开 >> Lipetsk, Lipetsk region, Russian Federation Saransk, Republic of Mordovia, Russian Federation Kazan, Republic of Tatarstan, Russian Federation Ekaterinburg, Sverdlovsk region, Russian Federation Moscow, Russian Federation Nizhny Novgorod, Russian Federation Novosibirsk, Russian Federation Saint-Petersburg, Russian Federation Tver, Russian Federation Yaroslavl, Russian Federation 收起 <<
NCT03353922	Driving Impaired	Phase 1	Completed	-	United States, California ... 展开 >> Collaborative Neuroscience Network Long Beach, California, United States, 92845 United States, Georgia NeuroTrials Research Atlanta, Georgia, United States, 30342 收起 <<
NCT01151787	Chronic Migraine	Phase 3	Terminated(Study was never ini... 展开 >>tiated under new location/provider group. Contract to continue was never signed between TEVA and Kennedy Headache Center) 收起 <<	-	United States, New Jersey ... 展开 >> The Headache Center at Kennedy Health Alliance Cherry Hill, New Jersey, United States, 08002 收起 <<
NCT02642861	Liver Cirrhosis	Phase 3	Not yet recruiting	December 2019	Egypt ... 展开 >> Tanta university - faculty of medicine Tanta, Egypt 收起 <<
NCT01921296	Sleep Initiation and Maintenan... 展开 >>ce Disorders Pain 收起 <<	Phase 2	Terminated(Accrual terminated ... 展开 >>early because of poor accrual) 收起 <<	-	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109-0944 收起 <<
NCT00778037	Healthy	Not Applicable	Completed	-	India ... 展开 >> Ranbaxy CPU Gurgaon, Haryana, India 收起 <<
NCT03443960	Healthy Subjects	Phase 1	Completed	-	Canada, Quebec ... 展开 >> Quebec City Quebec City, Quebec, Canada, G1P 0A2 收起 <<
NCT00790270	Cervical Strain	Phase 2	Completed	-	United States, New York ... 展开 >> Stony Brook University Stony Brook, New York, United States, 11733 收起 <<
NCT01921296	-		Terminated(Accrual terminated ... 展开 >>early because of poor accrual) 收起 <<	-	-

盐酸环苯扎林 /Cyclobenzaprine HCI {[allProObj[0].p_purity_real_show]}

Cyclobenzaprine HCI 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Cyclobenzaprine HCI 质控信息

Cyclobenzaprine HCI 生物活性

Cyclobenzaprine HCI 临床研究

Cyclobenzaprine HCI 参考文献

Cyclobenzaprine HCI 实验方案

Cyclobenzaprine HCI 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

盐酸环苯扎林 /Cyclobenzaprine HCI {[allProObj[0].p_purity_real_show]}

Cyclobenzaprine HCI 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Cyclobenzaprine HCI 质控信息

Cyclobenzaprine HCI 生物活性

Cyclobenzaprine HCI 临床研究

Cyclobenzaprine HCI 参考文献

Cyclobenzaprine HCI 实验方案

Cyclobenzaprine HCI 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cyclobenzaprine HCI 纯度/质量文件产品仅供科研